| Multiple Myeloma

Empliciti vs Tecvayli

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Empliciti vs Tecvayli with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTecvayli has a higher rate of injection site reactions vs Empliciti based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tecvayli but not Empliciti, including UnitedHealthcare

Category

Empliciti

Tecvayli

At A Glance

RouteIV infusion

FrequencyWeekly to every 4 weeks

ClassSLAMF7 antagonist

RouteSC injection

FrequencyWeekly to every 4 weeks

ClassBCMA-directed CD3 T-cell engager

Indications

Multiple Myeloma

Multiple Myeloma

Dosing

Multiple Myeloma (with lenalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.

Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 20 mg/kg every 4 weeks until disease progression or unacceptable toxicity.

Multiple Myeloma (combination with daratumumab and hyaluronidase-fihj) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 3), then 1.5 mg/kg once weekly (weeks 2-8), 3 mg/kg every 2 weeks (weeks 9-24), and 3 mg/kg every 4 weeks (week 25 onward); administer until disease progression or unacceptable toxicity.

Multiple Myeloma (monotherapy) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 4), then 1.5 mg/kg once weekly; may reduce to 1.5 mg/kg every 2 weeks for patients with complete response or better maintained for at least 6 months.

Contraindications

—

Drug Interactions

188View drug interactions

27View drug interactions

Adverse Reactions

Most common (>=10%) Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, pain in extremities, headache, vomiting, weight decreased, lymphopenia, cataracts, oropharyngeal pain

Serious Pneumonia, pyrexia, respiratory tract infection, anemia, pulmonary embolism, acute renal failure

Most common (>=20%) pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, diarrhea, hypogammaglobulinemia, cough, COVID-19, gastroenteritis, weight decreased

Serious pneumonia, cytokine release syndrome, sepsis, pyrexia, COVID-19, febrile neutropenia, gastroenteritis, acute kidney injury, encephalopathy, second primary malignancy

Pharmacology

Elotuzumab is a humanized IgG1 monoclonal antibody that targets SLAMF7 on myeloma cells and natural killer (NK) cells, directly activating NK cells through the SLAMF7 pathway and mediating killing of myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds CD3 on T-cells and BCMA on multiple myeloma cells, activating T-cells to release proinflammatory cytokines and lyse myeloma cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Empliciti